Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade for in-vivo purging in multiple myeloma
NCT02703779Phase 2Completed
- Start
- Mar 2016
- Primary completion
- Oct 2019
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bortezomib in multiple myeloma (MM). Started Mar 2016; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02703779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02703779.